Latest Trials

EudraCT Number: 2022-001528-14

Sponsor Protocol Number: 67484703ADM2001

Start Date: 2023-02-02

Sponsor Name: Janssen-Cilag International NV

Full Title: A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-67484703 in Participants with Atopic Dermatitis

Medical condition: Atopic Dermatitis

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004858	10003639	Atopic dermatitis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003050-32

Sponsor Protocol Number: FAB122-CT-2201

Start Date: 2023-01-27

Sponsor Name: Ferrer Internacional, S.A.

Full Title: A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis

Medical condition: Amyotrophic Lateral Sclerosis (ALS)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029205 - Nervous system disorders	10002026	Amyotrophic lateral sclerosis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000439-22

Sponsor Protocol Number: 67953964MDD3001_VENTURA-1

Start Date: 2023-01-25

Sponsor Name: Janssen-Cilag International NV

Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...

Medical condition: Major Depressive Disorder (MDD)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004873	10025453	Major depressive disorder NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Ongoing) ES (Ongoing) HU (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005947-58

Sponsor Protocol Number: M1095-PSA-201

Start Date: 2023-01-25

Sponsor Name: MoonLake Immunotherapeutics AG

Full Title: Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients with Active Psoriatic Arthritis

Medical condition: Active Psoriatic Arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004859	10037160	Psoriatic arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Ongoing) ES (Ongoing) HU (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001484-27

Sponsor Protocol Number: NL67672.091.18

Start Date: 2023-01-24

Sponsor Name: radboudumc

Full Title: B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissues Analysis 2

Medical condition: Systemic Sclerosis Sjögren's Syndrome Cutaneous Lupus Erythematodus

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002924-11

Sponsor Protocol Number: LOLAbiome

Start Date: 2023-01-09

Sponsor Name: CBmed GmbH

Full Title: An observational study on the effect of L-ornithine-L-aspertate (LOLA) on the Flavonifractor abundance in the gut microbiome in liver cirrhosis

Medical condition: Liver cirrhosis with covert or overt hepatic encephalopathy (grade 0-2)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004871	10024667	Liver cirrhosis	LLT
	20.0	100000004852	10014630	Encephalopathy hepatic	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: AT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000490-13

Sponsor Protocol Number: EstuEla2022

Start Date: 2023-01-09

Sponsor Name: OILS4CURE S.L

Full Title: Treatment, with a full spectrum extract of cannabis, in refractory epilepsy associated with tuberous sclerosis complex (TSC)

Medical condition: Refractory epilepsy in tuberous sclerosis complex

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003079-41

Sponsor Protocol Number: BOLD-100-001

Start Date: 2023-01-06

Sponsor Name: Bold Therapeutics, Inc. (Bold)

Full Title: A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours

Medical condition: Colorectal Cancer Pancreatic Cancer Gastric Cancers Cholangiocarcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004864	10052362	Metastatic colorectal cancer	LLT
	21.1	100000004864	10033605	Pancreatic cancer metastatic	LLT
	20.1	100000004864	10017770	Gastric carcinoma	LLT
	21.1	100000004864	10077846	Cholangiocarcinoma metastatic	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-004931-10

Sponsor Protocol Number: R3918-PNH-2050

Start Date: 2023-01-04

Sponsor Name: Regeneron Pharmaceuticals, Inc.

Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004857	10055629	Paroxysmal nocturnal hemoglobinuria	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GR (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001387-10

Sponsor Protocol Number: 220301

Start Date: 2022-12-29

Sponsor Name: TECNIMEDE, Sociedade Técnico-Medicinal, S.A.

Full Title: A Phase 3, Multicenter, Prospective, Placebo-Controlled, Randomized, Double-Blind Study to Assess the Efficacy and Safety of Favipiravir in Non-critical Hospitalized Patients with COVID-19 Pneumoni...

Medical condition: Coronavirus disease 2019 (COVID-19 pneumonia)

Disease:	Version	SOC Term	Classification Code	Term	Level
	25.1	100000004862	10066740	Acute respiratory tract infection	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PT (Ongoing)

Trial results: (No results available)

Latest Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions